Company

→ Our Values

At Moon Surgical

We build things that matter

We are driven by an intrinsic desire to advance global healthcare for patients, to innovate and inspire the art of surgery, and to make a difference through creativity, perseverance, and teamwork.

We believe the team is the product

We are cohesive, focused, hardworking, and dedicated. While also embracing humor, kindness, and understanding, all of which is reflected in our products.

We shoot for the Moon

We believe in setting ambitious yet attainable goals and overcoming challenges together, using each success as a launchpad for further exploration and innovation.

Want to join the team? Check out our open roles!

→ Open Roles

→ Our Story

Discover our journey to democratize digital robotics

June 2020

A Sofinnova MD Start portfolio company. Moon Surgical (originally MastOR), founded in Paris by Pr. Brice Gayet and joined by Anne Osdoit as CEO, receives seed funding and starts incubation with Sofinnova MD Start.

May 2021

Team Assembly Initial team of 8 is fully assembled, accelerating the development.

September 2021

First System The first fully integrated prototype, Apollo 12, is built.

May - December 2022

First-in-Human World renowned Pr. Guy-Bernard Cadière performs 50 procedures at CHU Saint-Pierre, a public university hospital in Brussels, Belgium.

May 2022

Series A Financing Moon Surgical raises $31.3 million in Series A funding to expand its team and accelerate the development of its Maestro robotic surgery system with GT Healthcare Capital & Partners and Johnson & Johnson Innovation.

December 2022

FDA clearance The first version (”First in Human”) of the Maestro System is cleared by the FDA.

April 2023

CE Mark The first version (”First in Human”) of the Maestro System receives CE mark.

May 2023

Series B Financing Moon Surgical raises an additional $55.4 million, in a round led by Sofinnova Partners and NVIDIA.

September - October 2023

Commercial Cases First commercial system cases are performed in France, by Dr. Benjamin Cadiere and Dr. Henry Mercoli.

April 2024

Two hundred procedures are successfully completed in EU Commercial Pilot in France.

June 2024

The commercial version of the Maestro system receives FDA clearance and is used to treat patients in the US.